Literature DB >> 187621

Urinary cyclic AMP analyzed as a function of the serum calcium and parathyroid hormone in the idfferential diagnosis of hypercalcemia.

J W Shaw, S B Oldham, L Rosoff, J E Bethune, M P Fichman.   

Abstract

Urinary cyclic AMP (UcAMP) appropriate for the serum calcium concentration was determined in normal subjects during the base-line state and during alteration in their serum calcium concentrations by saline and calcium infusions. This was compared to the UcAMP in 76 patients with hypercalcemia and 5 patients with hypocalcemia. In 54 of 56 patients with primary hyperparathyroidism, the UcAMP was inappropriately high for their serum calcium concentration, the 2 exceptions having renal failure. In four patients with vitamin D intoxication, sarcoidosis, milkalkali syndrome, and thiazide-induced hypercalcemia and in five patients with hypocalcemia due to hypoparathyroidism, the UcAMP was appropriately low for their serum calcium concentration. In 16 patients with nonparathyroid neoplasms, 10 had UcAMP levels that were inappropriately high suggesting ectopic parathyroid hormone (PTH)-mediated hypercalcemia and 6 had UcAMP levels that were appropriately low suggesting that their hypercalcemia was due to osteolytic factors other than PTH. Correlations between UcAMP, serum calcium concentration, and carboxyl-terminal immunoreactive PTH suggest that random UcAMP is a sensitive accurate reflection of circulating biologically active PTH. If there is adequate renal function (serum creatinine concentration less than 2.0 mg/dl), a random UcAMP expressed as mumol/g creatinine and analyzed as a function of the serum calcium concentration completely separates patients with PTH and non-PTH-mediated hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 187621      PMCID: PMC333327          DOI: 10.1172/JCI108611

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Circadian rhythm in the urinary excretion of cyclic 3',5'-adenosine monophosphate in man.

Authors:  J Sagel; J A Colwell; C B Loadholt; G Lizarralde
Journal:  J Clin Endocrinol Metab       Date:  1973-10       Impact factor: 5.958

2.  Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism.

Authors:  F A Neelon; B M Birch; M Drezner; H E Lebovitz
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

3.  Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease.

Authors:  R C Benson; B L Riggs; B M Pickard; C D Arnaud
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

4.  Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases.

Authors:  D Powell; F R Singer; T M Murray; C Minkin; J T Potts
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

5.  Parathyroid hormone: sequence, synthesis, immunoassay studies.

Authors:  J T Potts; T M Murray; M Peacock; H D Niall; G W Tregear; H T Keutmann; D Powell; L J Deftos
Journal:  Am J Med       Date:  1971-05       Impact factor: 4.965

6.  Malignant neoplasms and parathyroid adenoma.

Authors:  L Kaplan; A D Katz; C Ben-Isaac; S G Massry
Journal:  Cancer       Date:  1971-08       Impact factor: 6.860

7.  Parathyroid Hormone in Human Plasma: IMMUNOCHEMICAL CHARACTERIZATION AND BIOLOGICAL IMPLICATIONS.

Authors:  G V Segre; J F Habener; D Powell; G W Tregear; J T Potts
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

8.  Effects of parathyroid hormone on plasma and urinary adenosine 3',5'-monophosphate in man.

Authors:  N I Kaminsky; A E Broadus; J G Hardman; D J Jones; J H Ball; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria.

Authors:  C Y Pak; M Oata; E C Lawrence; W Snyder
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Radioimmunoassay of human parathyroid hormone in serum.

Authors:  C D Arnaud; H S Tsao; T Littledike
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

View more
  8 in total

1.  Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

Authors:  C Gennari; G Francini; M Galli; F Lore
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

2.  Recognizing hyperparathyroidism caused by ectopic production of a substance resembling parathyroid hormone.

Authors:  P Ernst; M Kaye
Journal:  Can Med Assoc J       Date:  1981-10-15       Impact factor: 8.262

3.  Hyperparathyroidism with asymptomatic hypercalcemia and symptomatic normocalcemia.

Authors:  L Thorén
Journal:  World J Surg       Date:  1977-11       Impact factor: 3.352

4.  Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts.

Authors:  M Peracchi; F Bamonti-Catena; B Bareggi; R Calori; A T Maiolo
Journal:  Blut       Date:  1990-03

5.  Metabolic aspects of bone resorption in calcium-deficient lactating rats.

Authors:  K M Wong; L Singer; R H Ophaug
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

6.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Seasonal variation in urinary excretion of cyclic AMP in healthy people.

Authors:  C Gennari; F Loré; M Galli; I D D'Amore; G Francini
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

8.  The 24-h urinary cyclic adenosine 3', 5' monophosphate/creatinine ratio: an useful approach to the diagnosis of parathyroid disorders and function.

Authors:  A Caniggia; R Nuti; M Galli
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.